Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Skincol
- Development stage
- Unknown
- Lead developer
- Lisapharma
- Administration
- Topical
01
Overview
Skincol is a topical medical device developed by Lisapharma, formulated as a sprayable humid gel containing sucralfate. It is indicated for the management of various skin lesions, including abrasions, first and second-degree burns, and pressure ulcers. The product functions by creating a protective physical barrier over the injured skin, which maintains a moist environment essential for the physiological healing process. Sucralfate, the active component, interacts with proteins in the wound exudate to form a bio-adherent film that shields the area from external contaminants and mechanical irritation.
- Brand names
- SkincolSkincol Spray
- Other names
- Sucralfate humid gel
Beyond the preview
Go deeper on Skincol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skincol.